Vaccination of travelers: how far have we come and where are we going?

References

• Steffen R, Amitirigala I, Mütsch M. Health risks among travellers – need for regular updates. J. Travel Med.15(3), 145–146 (2008).
   PubMedGoogle Scholar
• Steffen R. Hepatitis A and B: risks compared with other vaccine-preventable diseases and immunization recommendations. Vaccine11, 518–520 (1993).
   PubMedGoogle Scholar
• Nielsen US, Petersen E, Larsen CS. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J. Infect.59(5), 353–359 (2009).
   PubMed Web of Science ®Google Scholar
• CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-7), 1–23 (2006).
   PubMedGoogle Scholar
• Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis.171(Suppl. 1), S44–S49 (1995).
   PubMed Web of Science ®Google Scholar
• Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N. Engl. J. Med.357(17), 1685–1694 (2007).
   PubMed Web of Science ®Google Scholar
• CDC. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.56(41), 1080–1084 (2007).
   PubMedGoogle Scholar
• CDC. Surveillance for acute viral hepatitis – United States, 2007. MMWR Surveill. Summ.58(SS03), 1–27 (2009).
   PubMedGoogle Scholar
• Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep.57(RR-8), 1–28 (2008).
   PubMedGoogle Scholar
• Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of adults. MMWR Recomm. Rep.55(RR16), 1–40 (2006).
   PubMedGoogle Scholar
• CDC. Recommended adult immunization schedule – United States, 2011. MMWR Morb. Mortal. Wkly60(4), 1–4 (2011).
   PubMedGoogle Scholar
• McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis.200(9), 1390–1396 (2009).
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Knoll A, Lindner E et al. Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine19, 16–22 (2001).
   Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine17, 1657–1662 (1999).
   PubMed Web of Science ®Google Scholar
• CDC. Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR Morb. Mortal. Wkly Rep.50, 806–807 (2001).
   PubMedGoogle Scholar
• Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol.65(1), 6–13 (2001).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med. Infect. Dis.5(3), 171–175 (2007).
   PubMedGoogle Scholar
• Beran J, Kervyn D, Wertzova V et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine28(37), 5993–5997 (2010).
   PubMed Web of Science ®Google Scholar
• Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J. Travel Med.14(1), 9–15 (2007).
   PubMed Web of Science ®Google Scholar
• Kurugöl Z, Mutlubaş F, Ozacar T. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6–15 years. Vaccine23(22), 2876–2880 (2005).
   PubMedGoogle Scholar
• Duval B, Gîlca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8–10-year-old children. Vaccine23(31), 4082–4087 (2005).
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine26(14), 1759–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Overbosch D, Peyron F, Picot N et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J. Travel Med.12(6), 319–326 (2005).
   PubMed Web of Science ®Google Scholar
• Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K, Weber F. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine23(1), 29–35 (2004).
   PubMedGoogle Scholar
• Beran J, Chlibek R, Weber F. A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine21(32), 4650–4654 (2003).
   PubMedGoogle Scholar
• Manning SE, Rupprecht CE, Fishbein D et al.; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention – United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep.57(RR-3), 1–28 (2008).
   PubMedGoogle Scholar
• Rupprecht CE, Briggs D, Brown CM et al.; Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep.59(RR-2), 1–9 (2010).
   PubMedGoogle Scholar
• WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol. Rec.85(32), 309–320 (2010).
   Google Scholar
• Robertson K, Recuenco S, Niezgoda M, Garcia EJ, Rupprecht CE. Seroconversion following incomplete human rabies postexposure prophylaxis. Vaccine28(39), 6523–6526 (2010).
   PubMedGoogle Scholar
• Shantavasinkul P, Tantawichien T, Wacharapluesadee S et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin. Infect. Dis.50(1), 77–79 (2010).
   PubMed Web of Science ®Google Scholar
• Gautret P, Schwartz E, Shaw M et al.; GeoSentinel Surveillance Network. Animal-associated injuries and related diseases among returned travellers: a review of the GeoSentinel Surveillance Network. Vaccine25(14), 2656–2663 (2007).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Tavernini M, Marx A et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin. Infect. Dis.40, 1282–1287 (2005).
   PubMedGoogle Scholar
• CDC. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep.59(RR-8), 1–68 (2010).
   PubMedGoogle Scholar
• CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.59(RR-1), 1–27 (2010).
   PubMedGoogle Scholar
• Hills SI, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am. J. Trop. Med. Hyg.82, 930–936 (2010).
   PubMed Web of Science ®Google Scholar
• CDC. Japanese encephalitis in two children – United States, 2010. MMWR Morb. Mortal. Wkly Rep.60(9), 276–278 (2011).
   PubMedGoogle Scholar
• CDC. Japanese encephalitis among three US travelers returning from Asia, 2003–2008. MMWR Morb. Mortal. Wkly Rep.58(27), 737–740 (2009).
   PubMedGoogle Scholar
• Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine27(15), 2188–2193 (2009).
   PubMed Web of Science ®Google Scholar
• Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine26, 4382–4386 (2008).
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine28, 5197–5202 (2010).
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine26(48), 6151–6156 (2008).
   PubMed Web of Science ®Google Scholar
• Eder S, Dubischar-Kastner K, Firbas C et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine29, 2607–2612 (2011).
   PubMed Web of Science ®Google Scholar
• CDC. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine – Advisory Committee on Immunization Practices, 2011. MMWR Morb. Mortal. Wkly Rep.60(20), 661–663 (2011).
   PubMedGoogle Scholar
• Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomized controlled trial. Lancet370, 1847–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Schuller E et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine28, 834–839 (2010).
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Kadlecek V, Sablan B et al. Safety, immunogenicity and dose confirmation for the inactivated Japanese encephalitis vaccine IXIARO, IC51, in Filipino children aged 3 to 12 years. Abstracts from the 12th Conference of International Society of Travel Medicine. Boston, MA, USA (2011).
   Google Scholar
• CDC. Update on Japanese encephalitis vaccine for children –United States, may 2011. MMWR Morb. Mortal. Wkly Rep.60(20), 664–665 (2011).
   PubMedGoogle Scholar
• Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine29(18), 3363–3371 (2011).
   PubMedGoogle Scholar
• Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis.20(5), 454–460 (2007).
   PubMed Web of Science ®Google Scholar
• Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg.96, 242–249 (2002).
   PubMed Web of Science ®Google Scholar
• Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA260(18), 1686–2689 (1988).
   Google Scholar
• Memish ZA. Meningococcal disease and travel. Clin. Infect. Dis.34, 84–90 (2002).
   PubMedGoogle Scholar
• Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159(10), 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly Rep.58(37), 1042–1043 (2009).
   PubMedGoogle Scholar
• Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J.28(3), 186–193 (2009).
   PubMed Web of Science ®Google Scholar
• CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep.59(9), 273 (2010).
   PubMedGoogle Scholar
• Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev. Vaccines10(1), 21–33 (2011).
   PubMed Web of Science ®Google Scholar
• CDC. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep.60(3), 72–76 (2011).
   PubMedGoogle Scholar
• Monath TP. Yellow fever: an update. Lancet Infect. Dis.1(1), 11–20 (2001).
   PubMedGoogle Scholar
• WHO Yellow fever in Africa and Central and South America, 2008–2009. Wkly Epidemiol. Rec.86(4), 25–36 (2011).
   PubMedGoogle Scholar
• Jentes ES, Poumerol G, Gershman MD et al. for the Informal World Health Organization Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination 2010: an international collaborative effort. Lancet Infect. Dis. (2011) (In Press).
   PubMedGoogle Scholar
• WHO. International Health Regulations (2nd Edition). WHO Press, Geneva, Switzerland (2005).
   Google Scholar
• WHO. International Travel and Health. WHO Press, Geneva, Switzerland (2011).
   Google Scholar
• WHO. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol. Rec.83(12), 105 (2008).
   PubMedGoogle Scholar
• Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstien WA, Offit PA (Eds). Saunders, PA, USA, 959–1055 (2008).
   Google Scholar
• Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.59(RR-7), 1–27 (2010).
   PubMedGoogle Scholar
• Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine26(48), 6077–6082 (2008).
   PubMed Web of Science ®Google Scholar
• Guimard T, Minjolle S, Polard E et al. Short report: Incidence of yellow fever vaccine-associated neurotropic disease. Am. J. Trop. Med. Hyg.81(6), 1141–1143 (2009).
   PubMed Web of Science ®Google Scholar
• McMahon AW, Barwick Eidex R, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine25(10), 1727–1734 (2007).
   PubMed Web of Science ®Google Scholar
• Whittembury A, Ramirez G, Hernandez H et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine27(43), 5974–5981 (2009).
   PubMed Web of Science ®Google Scholar
• Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol.17(1), 118–126 (2010).
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol.183(12), 7919–7930 (2009).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis.198(4), 500–507 (2008).
   PubMed Web of Science ®Google Scholar
• Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med.205(13), 3119–3131 (2008).
   PubMed Web of Science ®Google Scholar
• Belsher JL, Gay P, Brinton M et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine25(50), 8480–8485 (2007).
   PubMed Web of Science ®Google Scholar
• Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet364(9438), 936 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn S, Twele-Montecinos L, Macdonald J, Webster P, Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ183(4), E243–E245 (2011).
   Google Scholar
• WHO. Global Advisory Committee on Vaccine Safety, 3–4 December 2009. Wkly Epidemiol. Rec.85(5), 29–33 (2010).
   PubMedGoogle Scholar
• CDC. Transmission of yellow fever vaccine virus through breast-feeding – Brazil, 2009. MMWR Morb. Mortal. Wkly Rep.59(5), 130–132 (2010).
   PubMedGoogle Scholar
• Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine24(6), 1421–1426 (2006).
   PubMed Web of Science ®Google Scholar
• Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine17, 283–285 (1999).
   PubMedGoogle Scholar
• Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect. Dis.168, 1520–1523 (1993).
   PubMed Web of Science ®Google Scholar
• Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg.87, 337–339 (1993).
   PubMed Web of Science ®Google Scholar
• Veit O, Niedrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis.48(5), 659–666 (2009).
   PubMed Web of Science ®Google Scholar
• WHO. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol. Rec.86(24), 241–256 (2011).
   PubMedGoogle Scholar
• CDC. Tick-borne encephalitis among U.S. travelers to Europe and Asia – 2000–2009. MMWR Morb. Mortal. Wkly Rep.59(11), 335–338 (2010).
   PubMedGoogle Scholar
• Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine25, 1470–1476 (2007).
   PubMed Web of Science ®Google Scholar
• Schoendorf I, Ternak G, Oroszlàn G, Nicolay U, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum. Vaccines2, 42–47 (2007).
   Google Scholar
• Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst. Rev. (1), CD000977 (2009).
   Google Scholar
• WHO. Cholera, 2010. Wkly Epidemiol. Rec.86(31), 325–339 (2011).
   PubMedGoogle Scholar
• Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile – a new humanitarian and diplomatic resource. N. Engl. J. Med.363(24), 2279–2282 (2010).
   PubMedGoogle Scholar
• Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin. Infect. Dis.52(11), 1343–1349 (2011).
   PubMed Web of Science ®Google Scholar
• Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis.6, 361–373 (2006).
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Steffen R, Jönsson B. Cost–benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers’ diarrhea. J. Travel Med.16(1), 28–34 (2009).
   PubMedGoogle Scholar
• Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med. Clin. North. Am.92(6), 1377–1390, x (2008).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep.12(3), 157–164 (2010).
   PubMedGoogle Scholar
• Wilder-Smith A, Schwartz E. Dengue in travelers. N. Engl. J. Med.353(9), 924–932 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Weld LH, Wilder-Smith A et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997–2006. Emerg. Infect. Dis.14(7), 1081–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med.354(2), 119–130 (2006).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev. Vaccines7(5), 569–578 (2008).
   PubMed Web of Science ®Google Scholar
• Monath TP. Dengue and yellow fever –challenges for the development and use of vaccines. N. Engl. J. Med.357(22), 2222–2225 (2007).
   PubMed Web of Science ®Google Scholar
• Lang J. Recent progress on sanofi pasteur’s dengue vaccine candidate. J. Clin. Virol.46(Suppl. 2), S20–S24 (2009).
   PubMed Web of Science ®Google Scholar
• McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis.197(5), 693–697 (2008).
   PubMed Web of Science ®Google Scholar
• Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine23(25), 3256–3263 (2005).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin.2(2), 60–67 (2006).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J. Travel Med.17(Suppl.), 1–2 (2010).
   PubMedGoogle Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis.50(Suppl. 2), S54–S65 (2010).
   PubMed Web of Science ®Google Scholar
• Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther.11(7), 969–985 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev. Vaccines10(5), 617–634 (2011).
   PubMed Web of Science ®Google Scholar
• Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev. Vaccines7(5), 597–611 (2008).
   PubMed Web of Science ®Google Scholar
• Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis.200(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med.359(24), 2521–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled Phase 3 trials. Vaccine28(50), 7993–8000 (2010).
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Ebringer A, Elmes N et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin.6(12), 1038–1046 (2010).
   PubMed Web of Science ®Google Scholar
• Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA106(27), 11300–11305 (2009).
   PubMed Web of Science ®Google Scholar
• Monath TP, Lee CK, Julander JG et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine28(22), 3827–3840 (2010).
   PubMed Web of Science ®Google Scholar
• Monath TP, Fowler E, Johnson CT et al. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med.364(14), 1326–1333 (2011).
   PubMed Web of Science ®Google Scholar